CSBio CSBio

X
[{"orgOrder":0,"company":"UCB Pharma S.A","sponsor":"Advanz Pharma","pharmaFlowCategory":"D","amount":"$98.0 million","upfrontCash":"$84.0 million","newsHeadline":"Advanz Pharma Announces Definitive Agreement to Acquire The Rights To A Portfolio Of Alprostadil Products","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"UCB Pharma S.A"},{"orgOrder":0,"company":"Hyloris Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$69.3 million","upfrontCash":"Undisclosed","newsHeadline":"Hyloris Pharmaceuticals Raises Approximately EUR 61.81 Million in Successful Initial Public Offering","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Hyloris Pharmaceuticals"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            This significant raise will support Hyloris’ strategy and will be used for the development of existing portfolio of product candidates, establishment of a commercial team in the United States, to fund the expansion of the pipeline, as well as for general corporate purposes.

            Lead Product(s): Sotalol Hydrochloride

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Undisclosed

            Deal Size: $69.3 million Upfront Cash: Undisclosed

            Deal Type: Public Offering June 26, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The alprostadil product portfolio consists of two established, niche, injectable Prostaglandin E1 formulations for the treatment of erectile disfunction and peripheral arterial occlusive disease.

            Lead Product(s): Alprostadil

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Advanz Pharma

            Deal Size: $98.0 million Upfront Cash: $84.0 million

            Deal Type: Agreement March 06, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY